U.S. markets open in 49 minutes
  • S&P Futures

    3,949.75
    +2.75 (+0.07%)
     
  • Dow Futures

    32,099.00
    +28.00 (+0.09%)
     
  • Nasdaq Futures

    12,648.00
    +3.25 (+0.03%)
     
  • Russell 2000 Futures

    1,748.50
    +10.10 (+0.58%)
     
  • Crude Oil

    66.07
    -0.67 (-1.00%)
     
  • Gold

    1,988.40
    +14.90 (+0.76%)
     
  • Silver

    22.55
    +0.08 (+0.37%)
     
  • EUR/USD

    1.0719
    +0.0048 (+0.45%)
     
  • 10-Yr Bond

    3.4210
    +0.0260 (+0.77%)
     
  • Vix

    26.39
    +3.40 (+14.79%)
     
  • GBP/USD

    1.2239
    +0.0065 (+0.53%)
     
  • USD/JPY

    131.3380
    -0.4650 (-0.35%)
     
  • Bitcoin USD

    28,330.18
    +1,017.46 (+3.73%)
     
  • CMC Crypto 200

    615.59
    +43.58 (+7.62%)
     
  • FTSE 100

    7,366.83
    +31.43 (+0.43%)
     
  • Nikkei 225

    26,945.67
    -388.12 (-1.42%)
     

Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.

Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.

Pfizer (NYSE: PFE) enjoyed a record year in 2022. The big drugmaker's revenue topped $100 billion. Its earnings per share soared 42% to $5.47, which translates to nearly $31.4 billion in profits. Both top- and bottom-line numbers set all-time highs.